重组人α-2b干扰素含片药效学试验

Study on pharmacodynamics of recombinant human interferon α-2b buccal tablets

目的观察重组人α-2b干扰素（rhIFN α-2b）舍片对体外、体内的抗病毒作用，为临床用药提供药理学依据。方法采用体外和体内抗病毒试验。结果rhIFN α-2b含片浓度为400～250000IU／mL时，对单纯疱疹病毒（HSV-1、HSV2）和水痘-带状疱疹病毒有明显抑制作用，并在31．2—1000IU／mL浓度时，对乙型肝炎病毒也有明显抑制作用。小鼠抗流感病毒试验表明，口含rhIFN α-2b 500～50000IU／只，能明显降低动物死亡率，并延长存活时间。结论rhIFN α-2h含片对体内、体外病毒均有明显的抑制作用。

Purpose To observe anti-virus action in vivo and in vitro of recombinant human interferon α-2tb buccal tablets（rhiFN α-2t）, offering pharmacological basis for clinical study. Methods Employing antivirus test in vivo and in vitro. Results rhIFN a-2b, 400 - 250 000 IU/mL, showed apparent inhibition efficacy against herpes simple virus （HSV-1, HSV-2）and against chicken pox--herpes zoster virus. When the concentration is 31.2 - 1 000 IU/mL, it showed apparent inhibition efficacy against hepatitis B virus too. When used in 500 - 50 000 IU per mouse,it can reduce animal mortality obviously and prolong their survival time. Conclusion rhIFN α-2b has anti-viruses function both in vivo and in vitro.